Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Up 380.1% in May

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 159,027 shares, an increase of 380.1% from the April 30th total of 33,126 shares. Approximately 5.0% of the company’s shares are sold short. Based on an average daily volume of 476,377 shares, the days-to-cover ratio is currently 0.3 days.

Silexion Therapeutics Stock Up 1,048.2%

SLXN traded up $4.48 during trading hours on Friday, reaching $4.91. 309,883 shares of the company’s stock traded hands, compared to its average volume of 17,532,698. The firm has a 50-day moving average price of $8.38 and a 200 day moving average price of $16.93. The firm has a market capitalization of $20.57 million, a PE ratio of -0.61 and a beta of -0.29. Silexion Therapeutics has a 52-week low of $0.23 and a 52-week high of $22.36.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($12.90) by $12.05. Equities analysts predict that Silexion Therapeutics will post -4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.